Spotlight on JLABS

Add this event to your calendar:
20/09/2017 13:00 20/09/2017 15:00 America/Chicago Spotlight on JLABS JLABS @ TMC , John P. McGovern Campus , Houston , TX 77021 JLABS @ TMC false DD/MM/YYYY

Spotlight on JLABS

JLABS @ TMC , John P. McGovern Campus , Houston , TX 77021

September 20, 2017 from 13:00 PM to 15:00 PM (CST)

$10 - $35

Interested in starting a company, investing, or just curious about the current state of innovation in Houston? Then YOU are invited to JLABS @ TMC on September 20th to meet, greet, and see short presentations on some of our standout companies. Space is limited, so don't miss out!

Did you know that JLABS @ TMC is home to nearly 35 emerging companies? On September 20th, JLABS will shine the spotlight on three of our resident companies: Courier Therapeutics, Intuitap, and Wntrix. Join us to see how they're moving innovation forward, right here in Houston. Please note that the presentations at this event will include publicly available, non-confidential information only.

Wednesday, September 20, 2017

11:15 AM | Registration Opens
11:30 AM | Networking Lunch
12:00 PM | Presentations
1:00 PM | Program Close

Presenting Companies:
Courier Therapeutics read more» 
Intuitap read more» 
Wntrix read more»

Please RSVP online so that we can get an accurate headcount for food and beverages. 

John P. McGovern Campus
2450 Holcombe Blvd, Suite J
Houston, TX 77021

Presenting Companies' Descriptions:
Courier is developing a platform technology for precise delivery of cytokines to NK and T cells. The core technology is based on observations about viral stealth proteins that have evolved over millions of years to target certain receptors with extremely high affinity. This enables us to eliminate off target effects of cytokine therapy while increasing efficacy. High dose IL2 therapy is relatively effective but has significant drawbacks in toxicity.

Courier has designed a fusion protein that eliminates the off-target effects. Responders to IL2 have highly durable responses, but serious toxicity is seen in the areas of hepatoxicity and vascular leak syndrome. There is a 2% patient death rate, and 50% of patients discontinue therapy due to the toxicity.

IntuiTap eliminates the guesswork, frustration, and pain from spinal punctures by providing physicians real-time visualization of the underlying vertebrae. The handheld and easy-to-use IntuiTap is the world’s first tactile imaging device designed specifically to help position and guide a spinal needle for lumbar punctures, anesthesia, and epidurals.

IntuiTap also eliminates the need for unreliable and cumbersome manometers for pressure measurement by incorporating a continuous, digital pressure sensor and readout. This minimizes the incidence of failure and allows physicians to quickly and accurately get the pressure data they need. Additionally, IntuiTap makes it easy to sequentially collect cerebrospinal fluid while minimizing the chance of exposure to potentially contaminated fluid.

Overall, IntuiTap’s cutting-edge technology improves efficiency, decreases procedural costs, and instills confidence in both clinicians and patients, alike.

The company is focused on developing antibody-based therapeutics against targets in the Wnt signaling pathway for the treatment of cancers that are driven by the intended targets. In particular, the company will license preclinical candidates from the co-founder of the company that target receptors mutated in significant populations of lung, liver, and colon cancer. The company will optimize the candidates and develop them into IND candidates.Wnt Signaling is mutated in almost 100% of colon cancer and 20-50% of liver cancer, and in a significant proportion of other types of solid tumors.  Several drugs targeting the Wnt system are under development.  However, currently there are no drugs targeting the Wnt system on the market as direct targeting of the system has been challenging due to various reasons. 

The co-founder Qingyun (Jim) Liu was the first to discover a novel ligand receptor system that regulate the Wnt signaling system with a driving role in lung adenocarcinoma.  This will allow Wntrix to overcome the challenges others have experiencedWnt Signaling is mutated in almost 100% of colon cancer and 20-50% of liver cancer, and in a significant proportion of other types of solid tumors. 



Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then has grown to eight locations including the Bay Area, Boston & Lowell, MA, Houston, Toronto and a ninth location, New York City, launching in 2018. For more information please visit

Event contact

Related content